Clinical Trials Logo

Filter by:
NCT ID: NCT04185363 Active, not recruiting - Clinical trials for Progressive Familial Intrahepatic Cholestasis (PFIC)

An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)

Start date: January 8, 2020
Phase: Phase 3
Study type: Interventional

The primary objective of this open label extension study is to evaluate the long-term safety and tolerability of maralixibat.

NCT ID: NCT04185337 Active, not recruiting - Malignant Neoplasm Clinical Trials

Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes

Start date: January 26, 2021
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies how well ultrasound-guided photoacoustic imaging works in telling the difference between healthy and cancerous inguinal (groin) lymph nodes and how well it can detect certain features of lymph nodes, including size and shape in patients with cancer. Ultrasound-guided photoacoustic is a non-invasive imaging method that can detect and display characteristics of lymph nodes based on the level of oxygen in the cells. This imaging method may provide more accurate tumor staging and prevent unnecessary surgical interventions.

NCT ID: NCT04184622 Active, not recruiting - Obesity Clinical Trials

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

SURMOUNT-1
Start date: December 4, 2019
Phase: Phase 3
Study type: Interventional

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.

NCT ID: NCT04184050 Active, not recruiting - Multiple Myeloma Clinical Trials

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Start date: March 1, 2020
Phase: Phase 1
Study type: Interventional

An open-label, Phase 1 study of HPN217 to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

NCT ID: NCT04183218 Active, not recruiting - Clinical trials for Stage III Lung Cancer AJCC v8

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

Start date: September 23, 2019
Phase:
Study type: Observational

This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent). Continuous cardiac monitoring with an implanted device may help to identify cardiac changes that would remain unnoticed, and facilitate the treatment of these early cardiac changes as part of standard care.

NCT ID: NCT04183062 Active, not recruiting - Clinical trials for Osteosarcoma Metastatic

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Start date: October 4, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study of an investigational drug, BIO-11006, for the treatment of lung metastases in pediatric patients with advanced osteosarcoma or Ewing's sarcoma. This study will enroll up to 10 patients aged between 5 and 21 at Nicklaus Children's Hospital in Miami, FL. Patients will receive BIO-11006 in addition to chemotherapy consisting of gemcitabine and docetaxel. This study will test the hypothesis that BIO-11006 will enhance the effect of the gemcitabine and docetaxel chemotherapy to treat lung metastases in osteosarcoma and Ewing's sarcoma.

NCT ID: NCT04182763 Active, not recruiting - Clinical trials for Pantothenate Kinase-Associated Neurodegeneration

CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)

Start date: December 4, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to learn more about how people with the condition pantothenate kinase-associated neurodegeneration (PKAN) respond to a specialized study product. We are hoping to find out if the study product is safe, what effects-good and bad-the study product causes, and whether the study product changes certain measures of disease in PKAN.

NCT ID: NCT04182633 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

MTT for Children With ASD Who Have Gastrointestinal Disorders

Start date: November 15, 2019
Phase: Phase 2
Study type: Interventional

The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating children with Autism Spectrum Disorder (ASD) and gastrointestinal problems (primarily constipation and/or diarrhea). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by a bowel cleanse, followed by 12 weeks of Fecal Microbiota (FM).

NCT ID: NCT04182620 Active, not recruiting - Atrial Fibrillation Clinical Trials

Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation

ULTRA-HFIB
Start date: July 8, 2020
Phase: N/A
Study type: Interventional

The purpose of the ULTRA-HFIB Pilot is to determine the role of adjunctive renal denervation (RDN) in the prevention of Atrial Fibrillation (AF) recurrence in patients scheduled for an AF ablation procedure. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sympathetic denervation (Intervention).

NCT ID: NCT04182516 Active, not recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Start date: November 25, 2019
Phase: Phase 1
Study type: Interventional

Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.